Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Advanced Enzyme Technologies develops and manufactures enzymes and probiotics using fermentation, serving human nutrition (digestive health supplements), animal nutrition, baking and food processing, and industrial bio-processing applications. It sells both proprietary enzyme products and custom blends to nutraceutical and food customers in India and the US. Revenue is driven by human nutrition exports, with R&D in enzyme strains as the core moat.
One of India's few sizeable listed enzyme makers.
Advanced Enzyme Tech Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Advanced Enzyme Tech Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 15.08 | 11.72 | 11.92 |
| Book value / share (₹) | 150.38 | 131.27 | 122.61 |
| Return on equity | 10.0% | 8.9% | 9.7% |
| Return on capital employed | 10.9% | 10.4% | 11.8% |
| Operating margin | 25.3% | 24.8% | 27.1% |
| Net margin | 23.3% | 21.0% | 21.9% |
| EBITDA | ₹229 Cr | ₹194 Cr | ₹204 Cr |
| Free cash flow | ₹104 Cr | ₹108 Cr | ₹99 Cr |
| Total debt | ₹21 Cr | ₹22 Cr | ₹25 Cr |
| Debt to equity | 0.01 | 0.01 | 0.02 |
| Interest coverage | 71.9 | 44.4 | 57.8 |
| Current ratio | 9.78 | 9.09 | 7.61 |
| Shares outstanding | 11,19,25,000 | 11,18,80,000 | 11,18,25,000 |
Open the full income statement, balance sheet and cash flow for ADVENZYMES →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.